131 related articles for article (PubMed ID: 37902395)
1. Plasma-derived human factor X concentrate for the treatment of patients with hereditary factor X deficiency.
Escobar MA; Kavakli K
Haemophilia; 2024 Jan; 30(1):59-67. PubMed ID: 37902395
[TBL] [Abstract][Full Text] [Related]
2. A review of the pharmacokinetics, efficacy and safety of high-purity factor X for the prophylactic treatment of hereditary factor X deficiency.
Payne J; Batsuli G; Leavitt AD; Mathias M; McGuinn CE
Haemophilia; 2022 Jul; 28(4):523-531. PubMed ID: 35499465
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency.
Austin SK; Kavakli K; Norton M; Peyvandi F; Shapiro A;
Haemophilia; 2016 May; 22(3):419-25. PubMed ID: 27197801
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic treatment of bleeding episodes in children <12 years with moderate to severe hereditary factor X deficiency (FXD): Efficacy and safety of a high-purity plasma-derived factor X (pdFX) concentrate.
Liesner R; Akanezi C; Norton M; Payne J
Haemophilia; 2018 Nov; 24(6):941-949. PubMed ID: 29707881
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in women and girls with hereditary factor X deficiency.
Kulkarni R; James AH; Norton M; Shapiro A
J Thromb Haemost; 2018 May; 16(5):849-857. PubMed ID: 29460388
[TBL] [Abstract][Full Text] [Related]
6. Plasma-derived human factor X concentrate for on-demand and perioperative treatment in factor X-deficient patients: pharmacology, pharmacokinetics, efficacy, and safety.
Shapiro A
Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):97-104. PubMed ID: 27797267
[TBL] [Abstract][Full Text] [Related]
7. Experience of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency undergoing surgery.
Escobar MA; Auerswald G; Austin S; Huang JN; Norton M; Millar CM
Haemophilia; 2016 Sep; 22(5):713-20. PubMed ID: 27217097
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of a high-purity plasma-derived factor X concentrate in subjects with moderate or severe hereditary factor X deficiency.
Austin SK; Brindley C; Kavakli K; Norton M; Shapiro A;
Haemophilia; 2016 May; 22(3):426-32. PubMed ID: 26879266
[TBL] [Abstract][Full Text] [Related]
9. Use of a High-Purity Factor X Concentrate in Turkish Subjects with Hereditary Factor X Deficiency: Post Hoc Cohort Subanalysis of a Phase 3 Study.
Öner AF; Celkan T; Timur Ç; Norton M; Kavaklı K
Turk J Haematol; 2018 May; 35(2):129-133. PubMed ID: 29545231
[TBL] [Abstract][Full Text] [Related]
10. Use of plasma-derived factor X concentrate in neonates and infants with congenital factor X deficiency.
Zimowski KL; McGuinn CE; Abajas YL; Schultz CL; Kaicker S; Batsuli G
J Thromb Haemost; 2020 Oct; 18(10):2551-2556. PubMed ID: 32613702
[TBL] [Abstract][Full Text] [Related]
11. Occurrence and management of severe bleeding episodes in patients with hereditary factor X deficiency.
Tarantino MD
Haemophilia; 2021 Jul; 27(4):531-543. PubMed ID: 34021672
[TBL] [Abstract][Full Text] [Related]
12. Plasma-derived Factor X therapy for treatment of intracranial bleeding in a patient with Factor X deficiency: a case report.
Grottke O; Moser O; Farrag A; Elbracht M; Orlikowsky T; Trepels-Kottek S
Transfusion; 2019 Jul; 59(7):2228-2233. PubMed ID: 30964547
[TBL] [Abstract][Full Text] [Related]
13. Plasma-derived factor X concentrate compassionate use for hereditary factor X deficiency: Long-term safety and efficacy in a retrospective data-collection study.
Huang JN; Liesner R; Austin SK; Kavakli K; Akanezi C
Res Pract Thromb Haemost; 2021 Jul; 5(5):e12550. PubMed ID: 34263102
[TBL] [Abstract][Full Text] [Related]
14. Role of individual factor X concentrate pharmacokinetic studies in perioperative management of AL amyloidosis-associated acquired factor X deficiency.
Lewis AR; Peffley N; Klompas AM; Ashrani AA
Transfusion; 2023 Sep; 63(9):1773-1777. PubMed ID: 37427705
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and treatment of inherited factor X deficiency.
Brown DL; Kouides PA
Haemophilia; 2008 Nov; 14(6):1176-82. PubMed ID: 19141158
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic treatment of severe factor X deficiency with prothrombin complex concentrate.
Kouides PA; Kulzer L
Haemophilia; 2001 Mar; 7(2):220-3. PubMed ID: 11260283
[TBL] [Abstract][Full Text] [Related]
17. Successful liver transplantation for a child with life-threatening recurrent bleeding episodes due to congenital factor X deficiency: a case report.
Bang SH; Oh SH; Kim KM; Song SM; Seo JJ; Yoo HW; Kim TH; Kim DY; Lee SG
Transplant Proc; 2012 Mar; 44(2):583-4. PubMed ID: 22506295
[TBL] [Abstract][Full Text] [Related]
18. Hereditary factor X deficiency in America survey: impact on quality of life and burden of disease in patients and caregivers.
Branchford B; Clark K; Stanford RH; Garner DA; Huang SP; Wolford E
Blood Coagul Fibrinolysis; 2024 Apr; 35(3):73-81. PubMed ID: 38305129
[TBL] [Abstract][Full Text] [Related]
19. Acquired Factor X Deficiency in Patients With Primary Light Chain Amyloidosis.
Dejhansathit S; Suvannasankha A
J Investig Med High Impact Case Rep; 2019; 7():2324709619832332. PubMed ID: 30947547
[TBL] [Abstract][Full Text] [Related]
20. Danazol therapy in factor X deficiency.
Mukhopadhyay S; Saxena R; Kashyap R; Choudhry VP
Haemophilia; 2001 Sep; 7(5):504-6. PubMed ID: 11554940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
